{
    "nct_id": "NCT05371964",
    "official_title": "An Open Label, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Patients With Myelofibrosis",
    "inclusion_criteria": "* Diagnosis of primary myelofibrosis (PMF) according to the revised World Health Organization (WHO) criteria or post-essential thrombocythemia-MF or post-polycythemia vera according to the International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) criteria.\n* Dynamic International Prognostic Scoring System (DIPSS) intermediate-1, intermediate-2 or high-risk MF.\n* Candidate for ruxolitinib treatment:\n\n  1. Part 1 participants only: On ruxolitinib treatment for at least 12 weeks with at least 4 consecutive weeks immediately prior to enrollment at a stable dose.\n  2. Part 2 participants only: Candidate for ruxolitinib treatment as assessed by the investigator and has not previously been treated with a JAK inhibitor.\n* Clinical signs/symptoms of MF demonstrated by one of the following:\n\n  1. Measurable splenomegaly demonstrated by either a palpable spleen measuring ≥5 cm below the left costal margin or a spleen volume ≥450 cm^3 by MRI or CT,\n  2. active symptoms of MF on the MFSAF v4.0.\n* Ineligible for or unwilling to undergo hematopoietic stem cell transplant at time of study entry.\n* Hematology laboratory test values within protocol defined limits.\n* Biochemical laboratory test values within protocol defined limits.\n* Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2.\n* Participants should follow protocol defined contraceptives procedures.\n* A woman of childbearing potential must have a negative serum or urine pregnancy test at screening.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Peripheral blood blast count of ≥10% or bone marrow blast count of ≥10%.\n* Prior treatment with JAK inhibitor.\n* Known allergies, hypersensitivity, or intolerance to imetelstat or ruxolitinib or excipients.\n* Prior treatment with imetelstat.\n* Major surgery within 28 days prior to enrollment.\n* Any investigational drug regardless of class or mechanism of action, hydroxyurea, chemotherapy, immunomodulatory or immunosuppressive therapy, corticosteroids >30 mg/day prednisone or equivalent ≤14 days prior to enrollment.\n* Prior history of hematopoietic stem cell transplant.\n* Prior history of partial or complete splenectomy.\n* Diagnosis or treatment for malignancy other than MF, except:\n\n  * Malignancy treated with curative intent and with no known active disease present for ≥3 years before enrollment.\n  * Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.\n  * Adequately treated cervical carcinoma in situ without evidence of disease.\n* Clinically significant cardiovascular disease.\n* Known history of human immunodeficiency virus (HIV) or any uncontrolled active systemic infection requiring IV antibiotics.\n* Active systemic hepatitis infection requiring treatment or any known acute or chronic liver disease unless related to MF. Carriers of hepatitis virus are permitted to enter the study.",
    "miscellaneous_criteria": ""
}